Cantor Fitzgerald Analysts Cut Earnings Estimates for Exagen

Key Points

• Cantor Fitzgerald has revised Exagen's FY2026 earnings per share (EPS) estimates from ($0.31) to ($0.68), maintaining an "Overweight" rating and a target price of $10.00.
• The current consensus estimate for Exagen's full-year earnings is ($0.88) per share, reflecting ongoing challenges for the company.
• Despite the downgrade, multiple analysts have rated Exagen as a "buy" with an average price target of $11.25, indicating some level of confidence in the company's potential.

Exagen Inc. (NASDAQ:XGN - Free Report) - Cantor Fitzgerald cut their FY2026 earnings per share estimates for Exagen in a report issued on Wednesday, July 30th. Cantor Fitzgerald analyst R. Osborn now forecasts that the company will post earnings of ($0.68) per share for the year, down from their prior forecast of ($0.31). Cantor Fitzgerald currently has a "Overweight" rating and a $10.00 price target on the stock. The consensus estimate for Exagen's current full-year earnings is ($0.88) per share.

Several other equities research analysts have also commented on the company. KeyCorp upgraded Exagen from a "sector weight" rating to an "overweight" rating and set a $12.00 price target for the company in a research note on Wednesday, July 30th. UBS Group restated an "overweight" rating on shares of Exagen in a research note on Thursday, May 15th. Craig Hallum began coverage on Exagen in a research note on Wednesday, July 23rd. They set a "buy" rating and a $12.00 price target for the company. Canaccord Genuity Group upped their price target on Exagen from $8.00 to $11.00 and gave the stock a "buy" rating in a research note on Wednesday, July 30th. Finally, BTIG Research restated a "buy" rating on shares of Exagen in a report on Wednesday, May 7th. Seven equities research analysts have rated the stock with a buy rating, According to MarketBeat.com, the stock has a consensus rating of "Buy" and a consensus price target of $11.25.

Exagen Trading Down 0.3%

Exagen stock traded down $0.03 during trading on Friday, hitting $8.83. The company's stock had a trading volume of 126,601 shares, compared to its average volume of 230,897. The stock has a market capitalization of $194.15 million, a price-to-earnings ratio of -9.92 and a beta of 1.61. The stock's fifty day moving average is $7.24 and its 200 day moving average is $5.49. Exagen has a 1-year low of $2.24 and a 1-year high of $9.10. The company has a debt-to-equity ratio of 1.06, a quick ratio of 4.95 and a current ratio of 4.95.

Exagen (NASDAQ:XGN - Get Free Report) last released its earnings results on Tuesday, July 29th. The company reported ($0.18) EPS for the quarter, meeting the consensus estimate of ($0.18). The firm had revenue of $17.20 million during the quarter, compared to analyst estimates of $16.25 million. Exagen had a negative return on equity of 130.38% and a negative net margin of 28.85%.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently bought and sold shares of XGN. Huntleigh Advisors Inc. lifted its holdings in Exagen by 5.7% during the 2nd quarter. Huntleigh Advisors Inc. now owns 87,861 shares of the company's stock worth $613,000 after buying an additional 4,753 shares during the last quarter. Acadian Asset Management LLC bought a new position in Exagen during the 1st quarter worth approximately $25,000. Palumbo Wealth Management LLC lifted its holdings in Exagen by 14.4% during the 1st quarter. Palumbo Wealth Management LLC now owns 99,205 shares of the company's stock worth $356,000 after buying an additional 12,501 shares during the last quarter. Toronto Dominion Bank bought a new position in Exagen during the 4th quarter worth approximately $3,655,000. Finally, Driehaus Capital Management LLC bought a new position in Exagen during the 4th quarter worth approximately $1,716,000. Hedge funds and other institutional investors own 75.25% of the company's stock.

About Exagen

Exagen Inc develops and commercializes various testing products under the AVISE brand in the United States. The company enables healthcare providers to care for patients through the diagnosis, prognosis, and monitoring of autoimmune and autoimmune-related diseases, including systemic lupus erythematosus (SLE) and rheumatoid arthritis (RA).